Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia
10.15264/cpho.2019.26.1.12
- Author:
Hyery KIM
1
Author Information
1. Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. taban@hanmail.net
- Publication Type:Multicenter Study
- Keywords:
Childhood;
Precursor cell lymphoblastic leukemia;
Prognosis;
Survival
- MeSH:
Clinical Protocols;
Humans;
Immunotherapy;
Leukemia;
Precursor Cell Lymphoblastic Leukemia-Lymphoma;
Prognosis;
Prospective Studies;
Survival Rate;
Transcriptome
- From:Clinical Pediatric Hematology-Oncology
2019;26(1):12-26
- CountryRepublic of Korea
- Language:English
-
Abstract:
In recent decades, survival rates for childhood acute lymphoblastic leukemia have improved remarkably, as demonstrated by risk-stratified, prospective multicenter studies. Treatment protocols have evolved and become better matched to both prognostic factors and treatment responses. Recently, new molecular prognostic factors have been discovered in leukemia genomic studies. New tumor subtypes with independent gene expression profiles have also been characterized. Furthermore, therapies targeted to specific candidate mutations are being identified to broaden therapeutic options for patients with poor prognoses. Many new drugs are in clinical trials and immunotherapy is attracting significant interest for the treatment of recurrent or refractory disease in childhood acute lymphoblastic leukemia.
